First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Published Online: 2024-06-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Alexander Stehle•Ann Janssens•Anna-Maria Fink•Arnon P Kater•Barbara Eichhorst•Can Zhang•Carsten U Niemann•Caspar da Cunha-Bang•Christian B Poulsen•Christof Schneider•Clemens Schulte•Daniel Heintel•Davide Rossi•Djamila E Issa•Eduardus F M Posthuma•Elisabeth Vandenberghe•Emily E Holmes•Eugen Tausch•Florian Simon•Gunnar Juliusson•Hein P J Visser•Henrik Frederiksen•Ilse Christiansen•Jan Dürig•Julia von Tresckow•Karl-Anton Kreuzer•Kirsten Fischer•Lisbeth Enggaard•Mar Bellido•Mark-David Levin•Matthias Ritgen•Matthias Vöhringer•Michael Gregor•Michael Hallek•Monika Brüggemann•Moritz Fürstenau•Nadine Kutsch•Neta Goldschmidt•Patrick Thornton•Philipp B Staber•Rudolf Benz•Sandra Robrecht•Sebastian Böttcher•Stephan Stilgenbauer•Tamar Tadmor•Thomas Nösslinger•Vesa Lindström
